Incyte | INCY - Debt


Incyte reported $40.41M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Exelixis USD 176.46M 3.38M Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 734M 7M Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025